BR112023024537A2 - Inibidores de alk2 cinase contendo imidazol, seus usos, composição farmacêutica, e kit - Google Patents
Inibidores de alk2 cinase contendo imidazol, seus usos, composição farmacêutica, e kitInfo
- Publication number
- BR112023024537A2 BR112023024537A2 BR112023024537A BR112023024537A BR112023024537A2 BR 112023024537 A2 BR112023024537 A2 BR 112023024537A2 BR 112023024537 A BR112023024537 A BR 112023024537A BR 112023024537 A BR112023024537 A BR 112023024537A BR 112023024537 A2 BR112023024537 A2 BR 112023024537A2
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitors
- kit
- pharmaceutical composition
- alk2 kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192822P | 2021-05-25 | 2021-05-25 | |
| PCT/US2022/030690 WO2022251188A2 (en) | 2021-05-25 | 2022-05-24 | Imidazole-containing inhibitors of alk2 kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024537A2 true BR112023024537A2 (pt) | 2024-02-06 |
Family
ID=84230377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024537A BR112023024537A2 (pt) | 2021-05-25 | 2022-05-24 | Inibidores de alk2 cinase contendo imidazol, seus usos, composição farmacêutica, e kit |
Country Status (23)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405848A (en) * | 1993-12-22 | 1995-04-11 | Ortho Pharmaceutical Corporation | Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors |
| BR0111754A (pt) * | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
| JP2012504157A (ja) * | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式jakキナーゼ阻害剤 |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| JP7659269B2 (ja) * | 2018-12-21 | 2025-04-09 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見 |
-
2022
- 2022-05-24 GE GEAP202416425A patent/GEAP202416425A/en unknown
- 2022-05-24 CA CA3219966A patent/CA3219966A1/en active Pending
- 2022-05-24 BR BR112023024537A patent/BR112023024537A2/pt unknown
- 2022-05-24 CN CN202280037483.5A patent/CN117529315A/zh active Pending
- 2022-05-24 UY UY0001039788A patent/UY39788A/es unknown
- 2022-05-24 PE PE2023003085A patent/PE20250022A1/es unknown
- 2022-05-24 JP JP2023571902A patent/JP2024520359A/ja active Pending
- 2022-05-24 EP EP22811963.2A patent/EP4346806A4/en active Pending
- 2022-05-24 AR ARP220101377A patent/AR125963A1/es unknown
- 2022-05-24 MX MX2023013742A patent/MX2023013742A/es unknown
- 2022-05-24 KR KR1020237042819A patent/KR20240013145A/ko active Pending
- 2022-05-24 AU AU2022283258A patent/AU2022283258A1/en active Pending
- 2022-05-24 IL IL308513A patent/IL308513A/en unknown
- 2022-05-24 PY PY202202240952A patent/PY2240952A/es unknown
- 2022-05-24 WO PCT/US2022/030690 patent/WO2022251188A2/en not_active Ceased
- 2022-05-24 CR CR20230597A patent/CR20230597A/es unknown
- 2022-05-24 US US18/562,115 patent/US20240270750A1/en active Pending
- 2022-05-25 TW TW111119373A patent/TW202313625A/zh unknown
-
2023
- 2023-11-16 DO DO2023000254A patent/DOP2023000254A/es unknown
- 2023-11-23 JO JOJO/P/2023/0303A patent/JOP20230303A1/ar unknown
- 2023-11-24 CL CL2023003503A patent/CL2023003503A1/es unknown
- 2023-12-20 CO CONC2023/0017975A patent/CO2023017975A2/es unknown
- 2023-12-22 EC ECSENADI202396182A patent/ECSP23096182A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY39788A (es) | 2023-01-31 |
| JP2024520359A (ja) | 2024-05-24 |
| IL308513A (en) | 2024-01-01 |
| PY2240952A (es) | 2022-12-26 |
| EP4346806A2 (en) | 2024-04-10 |
| DOP2023000254A (es) | 2023-12-29 |
| US20240270750A1 (en) | 2024-08-15 |
| CA3219966A1 (en) | 2022-12-01 |
| AR125963A1 (es) | 2023-08-30 |
| ECSP23096182A (es) | 2024-01-31 |
| JOP20230303A1 (ar) | 2023-11-23 |
| MX2023013742A (es) | 2023-11-28 |
| WO2022251188A3 (en) | 2023-01-05 |
| AU2022283258A1 (en) | 2024-01-04 |
| KR20240013145A (ko) | 2024-01-30 |
| PE20250022A1 (es) | 2025-01-07 |
| CR20230597A (es) | 2024-02-20 |
| CL2023003503A1 (es) | 2024-05-03 |
| WO2022251188A8 (en) | 2024-01-04 |
| WO2022251188A2 (en) | 2022-12-01 |
| CO2023017975A2 (es) | 2024-01-15 |
| EP4346806A4 (en) | 2025-07-23 |
| CN117529315A (zh) | 2024-02-06 |
| TW202313625A (zh) | 2023-04-01 |
| GEAP202416425A (en) | 2024-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
| MX2022008881A (es) | Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112021025445A2 (pt) | Composto, composição farmacêutica, uso de um composto e método para o tratamento ou profilaxia de câncer e para o tratamento ou profilaxia de câncer de pulmão de células não pequenas | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| BR112022000431A2 (pt) | Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase | |
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
| BRPI0813244B8 (pt) | compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| BRPI0606107A2 (pt) | compostos farmacêuticos, seus proocessos de preparação, usos dos mesmos na fabricação de medicamento e composição farmacêutica compreendendo os referidos compostos | |
| EA201300288A1 (ru) | Имидазо[4,5-c]хинолины в качестве ингибиторов днк-пк | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
| BR112022018067A2 (pt) | Aminas de pirrolopirimidina como inibidores de complemento | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| GEAP202516720A (en) | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| MX2025014449A (es) | Derivados de heteroarilo como inhibidores de receptores de dominio de discoidina (ddr) | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
| MX2024009608A (es) | Compuestos heterociclicos y metodos de uso. |